This clinical trial aims to explore the effectiveness and safety of cognitive function improvement of Neuclare, a science medical device, for patients with mild cognitive impairment and early Alzheimer's disease.

Through methods such as Trail Making Test Black & White, Attention Questionnaire Scale(AQS), Neuropsychiatric Inventory (NPI), etc, cognitive function improvement before and after using Neuclare will be evaluated.

Inclusion Criteria:

• Adults aged 55 to 90
• Patients who meet "Probable Alzheimer's disease" and "Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)" criteria for dementia
• Patients with CDR (clinical dementia rating) from 0.5 to 1 and MMSE-II over 18
• Upon hearing and fully understanding the detailed explanation of this clinical trial, a person who has voluntarily decided to participate and agreed in writing to comply with the precautions

Exclusion Criteria:

• Patient with pathological lesions in the brain identified by MRI
• Patients with metabolic disorders such as thyroid dysfunction, hyperglycemia, hypoglycemia, liver or kidney dysfunction, and long-term use of drugs that will cause cognitive decline (e.g., anticholinergic drugs)
• History of epileptic seizures or depression or psychiatric abnormalities or with visual acuity and fluctuations in cognitive decline
• History of psychiatric disorder other than the inclusion criteria.
• A person with a severe history of cancer/tuberculosis
• A person who has or is taking psychiatric or peripheral/central nervous system drugs
• A person who has contact dermatitis or sensitive skin abnormalities
• Patients with a high fever of 40 degrees or higher based on eardrum body temperature
• A person whose bleeding is identified within the last 3 months due to a common procedure/surgery that may affect vital signs
• A person who is unable to perform MRI tests
• Pregnant women
• Patient with calcification in the brain identified by CT
• Patient with allergic to contrast agents such as Definity or Gadovist
• Other cases where the investigator judged that it is difficult to participate in the study;